Inion appoints Collins Stewart as Joint Broker

Tampere, Finland and Takeley, UK. 7 November 2005…Inion [LSE: IIN.L], a rapidly growing company focused on the development of novel biodegradable medical implants, has appointed Collins Stewart as Joint Broker alongside
Piper Jaffray.

05_INI_19 CS appt FINAL 071105.doc (142.85 kilobytes)

-Ends-

For further information, please contact:

Inion Oy      

Dr Auvo Kaikkonen, Chief Executive Officer    Tel: +358 3 230 6600

Tim Hirst, Corporate Communications           Tel: +44 (0)1279 874 222

Collins Stewart

Miikka Haromo                                                    Tel: +44 (0)20 7523 8000

Citigate Dewe Rogerson

Mark Swallow / Helena Podd                            Tel: +44 (0)207 638 9571

About Inion (www.inion.com)

Inion Oy is a Finnish company that specializes in the development of biodegradable medical implants.

The Inion core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes that are used to enhance the healing of skeletal injuries (bone and soft tissue), such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion OPTIMA™ family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation.

Inion has developed and launched products in four strategic business areas – cranio-maxillofacial surgery, orthopaedic trauma, sports medicine and dental surgery – in more than 40 countries worldwide. In addition, the Company has recently received a CE Mark for its first biodegradable product in the significant spinal implant area.

Inion was incorporated in early 2000 by an international team of experts in biodegradable materials and their clinical applications, and listed on the Official List of the UK Listing Authority in December 2004. The Company’s has operations in the UK, R&D and production facilities in Tampere, Finland, and a US office in Oklahoma City, OK.